Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
暂无分享,去创建一个
Vijay T. Ahuja | A. Srivastava | A. Narayan | S. Narayanan | V. Ramachandran | S. Bharath | R. Shandil | V. Sambandamurthy | R. Mclaughlin | James D. Whiteaker | H. Gardner | C. Sadler | Vaishali Humnabadkar | Jyothi Mahadevaswamy | Sreevalli Sharma | Disha Awasthy | Pravin S. Shirude | V. Shinde | Anisha Ambady | J. Reddy | Vijender Panduga | K. Prabhakar | S. Guptha | P. Iyer | V. Hosagrahara | S. Solapure | M. Chatterji | C. Bathula | Naveen V Kumar | Chandan Narayan | S. Hameed | R. Kale | M. Ramaiah | P. Madhavapeddi | M. Naik | P. Kaur | Naina Hegde | K. Vishwas | N. Choudhury | Robert E. McLaughlin | KG Vishwas
[1] Peter G. Schultz,et al. University of Birmingham Identification of a small molecule with activity against drug-resistant and persistent tuberculosis , 2013 .
[2] Jon Cohen,et al. Infectious disease. Approval of novel TB drug celebrated--with restraint. , 2013, Science.
[3] R. Read,et al. Supplementary Materials for Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis , 2012 .
[4] K. Floyd,et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments , 2012, The Lancet.
[5] Lisa K. Woolhiser,et al. Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs against Mycobacterium tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.
[6] Vadim Makarov,et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. , 2010, Journal of the American Chemical Society.
[7] Stewart T. Cole,et al. Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.
[8] P. Brennan,et al. Decaprenylphosphoryl Arabinofuranose, the Donor of the d-Arabinofuranosyl Residues of Mycobacterial Arabinan, Is Formed via a Two-Step Epimerization of Decaprenylphosphoryl Ribose , 2005, Journal of bacteriology.
[9] E. Kantharaj,et al. Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[10] L. Wayne,et al. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.